Operator
The next question comes from Raju Prasad with William Blair.
Raju Prasad
With the CYAD-02 data upcoming at the end of the year, can you just give us some context over on what you're looking for in the program, obviously, with the shift to allogeneic with the platform potential there. I just wanted to hear your thoughts on how to kind of frame that data? And then I have one other one.
Filippo Petti
Yes. Thanks, Raju. Appreciate the question. Maybe I'll throw my first remarks out there and then turn it over to Charlie for some additional thoughts. But look, I think from the autologous AML program and franchise that we've had, both the legacy program, the current CYAD-02. I think we've always kind of steered towards our discussions with KOLs and what would be meaningful for patients with that -- with those indications, I should say.
And really around 25%, 30% CR rate, I think, has been paramount. And thinking about having a duration of response there that goes out several months to us, that is going to be a key attribute to better assess the true potential of autologous CAR-T for the treatment of that disease. So I think we continue to lean on those thoughts, but let me hand it over to Charlie as well who can provide some additional context.
Charlie Morris
Thank you, Filippo. I mean, yes, so we continue to look for evidence of robust clinical activity. And as I said in my opening remarks, we will explore the idea of whether that is active enough to then discuss with potential collaborators whether there is a path forward.
I think it's also important for us to continue to understand NKG2D as a target. NKG2D obviously, is a core element of where we will be going, not just with 101, which we'll continue to have, but it's also -- the targets involved in 2003 as well. So we -- there's still much that we can learn to assist the other programs as well. So I think we can take learnings from the autologous to the allogeneic. And if we're seeing robust activity, then we have an opportunity for discussions with potential partners.
Raju Prasad
And then and I wanted to get your -- also your thoughts on with the hemalignancy platform programs to -- on consolidation versus a redosing paradigm, and we're hearing more about consolidation regimens to push responses deeper in hemalignancies, in particular. I just want to get your thoughts on how you're looking at the redosing paradigm versus consolidation as the immunity trial progresses?
Filippo Petti
Charlie?
Charlie Morris
I think one of the major potential advantages for any allogeneic platform is that we do have the potential to do exactly what you're describing to redose with the aim to push further. And it's certainly something that we intend to explore in our hemalignancy programs as we go forward. I think the -- it's much more of a challenge, obviously, in the autologous space because of the degree of preparation at the patient level that's required, but with an off-the-shelf product, we can use it much more in a typical sort of biologic paradigm, and it's certainly one that we intend to look at. We can look at it both ways, but I think that redosing sort of almost a cyclical way is certainly something that we will explore over time.
David Gilham
May I add to that, Filippo?
Filippo Petti
Please go ahead, David. Thank you.
David Gilham
Yes. So I enjoyed your note earlier as well as looking at some redosing strategies. I think it comes down -- as Charlie was highlighting, I think allogeneic technology gives the opportunity to think -- to work in either situation. I would say in the consolidation, where we would consider giving doses at a time point later on and perhaps just cells on their own, that would probably require some further engineering of the yellow cells to consider avoiding the immune response and much more thinking about the transplant situation, much like the autologous CAR-T situation is used.
One of the big advantages of the fact that allogeneic cells with the modifications they have to avoid GvHD, but not avoiding the host response is the fact that those cells persist for a very relatively short period of time, for weeks. And so that really does, I think, fits in with the potential of thinking about a redosing regimen over time. And as Charlie says, really think about this as a drug type paradigm, which, frankly, is just not really feasible in your autologous setting.
Operator
This concludes our question-and-answer segment. I would like to turn the conference back over to management for any closing remarks.
Filippo Petti
Great. Thank you, operator. I'd like to thank everyone for joining us today and certainly, your interest in Celyad Oncology. We remain steadfast in our mission to bring novel and innovative CAR-T therapies to cancer patients with unmet medical needs. And we look forward to speaking with you all again soon. Thank you, and have a great day.
Operator
The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.